Ossium Health announced today that the first patient has been treated with its newly released OssiGraft™ viable bone matrix (VBM) allograft in an ankle surgery. OssiGraft is Ossium’s viable bone matrix allograft, which is intended for use in orthopedic surgery to repair, replace, or reconstruct bone defects. This surgery represents Ossium’s transition from a clinical-stage company to a commercial company as well as its introduction to the orthopedic biologics market.

Read the press release here.